Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2013 May;4(5):772-84.
doi: 10.18632/oncotarget.1028.

Revisiting clinical trials using EGFR inhibitor-based regimens in patients with advanced non-small cell lung cancer: a retrospective analysis of an MD Anderson Cancer Center phase I population

Jennifer Wheler  1 , Gerald Falchook, Apostolia M Tsimberidou, David Hong, Aung Naing, Sarina Piha-Paul, Su S Chen, John Heymach, Siqing Fu, Bettzy Stephen, Jansina Y Fok, Filip Janku, Razelle Kurzrock
Affiliations
Clinical Trial

Revisiting clinical trials using EGFR inhibitor-based regimens in patients with advanced non-small cell lung cancer: a retrospective analysis of an MD Anderson Cancer Center phase I population

Jennifer Wheler et al. Oncotarget. 2013 May.

Abstract

Purpose: Single-agent EGFR inhibitor therapy is effective mainly in patients with lung cancer and EGFR mutations. Treating patients who develop resistance, or who are insensitive from the outset, often because of resistant mutations, other aberrations or the lack of an EGFR mutation, probably requires rational combinations. We therefore investigated the outcome of EGFR inhibitor-based combination regimens in patients with heavily-pretreated non-small cell lung cancer (NSCLC) referred to a Phase I Clinic.

Methods: We reviewed the electronic records of patients with NSCLC treated with an EGFR inhibitor-based combination regimen: erlotinib and cetuximab; erlotinib, cetuximab and bevacizumab; erlotinib and dasatinib; erlotinib and bortezomib; or cetuximab and sirolimus.

Results: EGFR mutations were detected in 16% of patients (21/131). EGFR inhibitor-based combination regimens were administered to 15 patients with EGFR-mutant NSCLC and 24 with EGFR wild-type disease. Stable disease (SD) ≥6 months/partial remission (PR) was attained in 20% of EGFR-mutant patients (3/15; two with sensitive mutations and secondary resistance to prior erlotinib, and one with a resistant mutation), as well as 26% of evaluable patients (5/19) with wild-type disease. One of three evaluable patients with squamous cell histology achieved SD for 26.5 months (EGFR wild-type, TP53-mutant, regimen=erlotinib, cetuximab and bevacizumab).

Conclusions: Eight of 34 evaluable patients (24%) with advanced, refractory NSCLC evaluable for response achieved SD ≥6 months/PR (PR=3; SD ≥6 months=5) on EGFR inhibitor-based combination regimens (erlotinib, cetuximab; erlotinib, cetuximab and bevacizumab; and, erlotinib, bortezomib), including patients with secondary resistance to single-agent EGFR inhibitors, resistant mutations, wild-type disease, and, squamous histology.

PubMed Disclaimer

Figures

Figure 1
Figure 1. 3-D Waterfall plot
Best response by RECIST, of 15 NSCLC patients with EGFR positive-mutations treated with an EGFR inhibitor-based regimen. Patients with clinical progression or with new metastases were graphed as 20% progression. Time to treatment failure in months is represented by solid lines and the arrow indicates that the patient was still on study when the data was censored. Patients with PIK3CA mutations in addition to EGFR mutation and patients who received prior EGFR inhibitor therapy are designated as such. Dotted horizontal line at -30% indicates border for partial response.
Figure 2
Figure 2. Computed tomography (CT) scans of a NSCLC patient (case #5, Table 2) with two sensitive EGFR mutations (L858R in exon 21 and G873E in exon 21) and a PIK3CA mutation (E542K in exon 9)
a) CT at baseline, and b) CT taken 5 months after treatment initiation with erlotinib/cetuximab/bevacizumab demonstrating a PR (-55%). Duration of response = 9+ months. Patient had received prior erlotinib for 14.3 months.
Figure 3
Figure 3. Kaplan-Meier estimates of time to treatment failure in 24 NSCLC patients with EGFR wild-type disease treated with EGFR inhibitor-based combination therapies
in phase I clinical trial program (3.3 months) vs. time to treatment failure on their last standard therapy (2.3 months; p=0.045; log-rank test)
See this image and copyright information in PMC

References

    1. Sharma SV, Bell DW, Settleman J, Haber DA. Epidermal growth factor receptor mutations in lung cancer. Nat Rev Cancer. 2007;7(3):169–181. - PubMed
    1. Chintala L, Kurzrock R. Epidermal growth factor receptor mutation and diverse tumors: case report and concise literature review. Mol Oncol. 2010;4(4):306–308. - PMC - PubMed
    1. Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, Harris PL, Haserlat SM, Supko JG, Haluska FG, Louis DN, Christiani DC, Settleman J, Haber DA. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med. 2004;350(21):2129–2139. - PubMed
    1. Riely GJ, Pao W, Pham D, Li AR, Rizvi N, Venkatraman ES, Zakowski MF, Kris MG, Ladanyi M, Miller VA. Clinical course of patients with non-small cell lung cancer and epidermal growth factor receptor exon 19 and exon 21 mutations treated with gefitinib or erlotinib. Clin Cancer Res. 2006;12(3 Pt 1):839–844. - PubMed
    1. Janku F, Garrido-Laguna I, Petruzelka LB, Stewart DJ, Kurzrock R. Novel therapeutic targets in non-small cell lung cancer. J Thorac Oncol. 2011;6(9):1601–1612. - PubMed

Publication types

MeSH terms